Group 1 - The core point of the article is that David Medical (300314) has approximately 18,600 shareholders as of January 30, 2026 [1]

祥生医疗2025年三季报显示，前三季度公司主营收入3.43亿元，同比下降5.27%；归母净利润9392.05万 元，同比下降4.56%；扣非净利润8696.66万元，同比下降2.69%；其中2025年第三季度，公司单季度主 营收入1.07亿元，同比下降6.68%；单季度归母净利润2422.41万元，同比上升41.95%；单季度扣非净利 润2314.06万元，同比上升53.63%；负债率11.24%，投资收益301.23万元，财务费用-1652.62万元，毛利 率59.82%。祥生医疗（688358）主营业务：超声医学影像设备的研发、制造和销售,为国内外医疗机 构、科研机构、战略合作伙伴等提供各类超声医学影像设备和专业的技术开发服务。 该股最近90天内共有3家机构给出评级，买入评级3家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算 ...

Core Viewpoint - Aomei Medical announced that it will disclose its 2025 annual performance forecast on January 31, 2026, in response to investor inquiries on its interactive platform [2] Group 1 - The company is set to release its annual performance forecast for 2025 [2]

了解本次路演活动，请点击： 浙江海圣医疗器械股份有限公司向不特定合格投资者公开发行股票并在北交所上市网上路演于2026年2 月3日14:00-16:00在全景路演举行。 路演现场，公司方在回复投资者提问时表示，公司核心技术的产业化应用成效显著。针对传统医疗产品 存在的操作不便、性能不佳、交叉感染等诸多技术难题，公司通过技术创新让产品在安全性、小型化、 数据精度以及用户体验方面具备突出行业优势。公司产品可灵活适用于多种复杂的临床应用场景，深度 覆盖不同科室的多样化需求。有效提升医护人员的工作效率，增强下游客户的产品使用黏性。 ...

Core Viewpoint - Zhejiang Medical Equipment Co., Ltd. is conducting a public offering of shares and will hold an online roadshow on February 3, 2026, showcasing its strong market position in the anesthesia and monitoring medical device sector [1] Group 1: Company Overview - The company has over 20 years of experience in the anesthesia and monitoring medical device industry, establishing itself as a leading brand with significant market influence [1] - Its products are widely used in over a thousand tertiary hospitals and thousands of medical institutions across the country, including more than 600 top-tier hospitals [1] - The company holds a prominent market share in its sector [1] Group 2: International Market Presence - The company has obtained 2 FDA (510K) registrations in the United States and 12 CE certifications in the European Union [1] - Its clientele includes internationally renowned medical device companies such as Medtronic and Abbott [1]

Core Viewpoint - The company is focusing on enhancing its research and innovation efforts while also prioritizing external growth opportunities through mergers, acquisitions, and strategic partnerships to expand its business scope and develop a second growth curve [1] Group 1: Research and Innovation - The company is continuously increasing its investment in research and innovation [1] - There is a strategic shift from diagnostics to a full industry chain layout that includes both "diagnostics + treatment" [1] Group 2: Business Expansion - The company aims to steadily expand its business areas through mergers, equity participation, and strategic collaborations [1] - The focus is on cultivating a second growth curve to promote high-quality and sustainable development [1] Group 3: Financial Management - The company is exercising caution in its financial management to enhance long-term value [1] - There is a commitment to returning value to investors who have placed their trust in the company [1]

瑞财经 吴文婷近日，明智科技股份有限公司（以下简称"明智科技"）在港交所递交招股书，建银国际 为其独家保荐人。 明智科技是一家平台型医疗器械公司，凭借创新可视化与微创医疗器械，在一次性泌尿科内窥镜领域处 于领先地位。公司于硅谷及中国营运，专注于一次性内窥镜系统的研发和商业化。公司是全球极少数成 功实现一次性内窥镜供应链垂直整合的公司之一，涵盖从核心光电组件及精密零件的自主研发制造，到 完整系统的组装全过程。 根据灼识谘询的资料，按2024年出货量计算，明智科技位列美国、欧洲及日本一次性输尿管镜市场前三 大品牌。截至最后实际可行日期，公司在全球主要市场(包括美国、欧盟及中国)拥有8个已获批产品类 别以及5个在研产品类别。 据招股书，2023年-2024年，明智科技实现收入分别为1.35亿元、1.41亿元；年内利润分别为4999万元、 6666.6万元。 IPO前，韦锡波通过USTCTEK持有公司股份43.83%，刘戈平博士通过JadeOcean Tek持有公司股份 23.85%，韦锡义通过WeiNova持有公司股份18.74%，邱小丽女士通过QiuStar持有公司股份4.98%，Wei Sara Shi女士持股 ...

Core Viewpoint - Sanofi Bio (300298.SZ) has repurchased a total of 13,691,161 shares, representing 2.44% of the company's current total share capital, in accordance with its established repurchase plan and relevant legal regulations [1] Summary by Category - **Share Repurchase Details** - The repurchase was conducted through a dedicated securities account via centralized bidding [1] - The highest transaction price was 21.39 CNY per share, while the lowest was 17.27 CNY per share [1] - The total amount spent on the repurchase was 261,941,012.29 CNY, excluding transaction fees [1]

Core Viewpoint - The company, Da An Gene (002030), indicated that its 2025 annual performance forecast is based on preliminary calculations by the finance department, with performance fluctuations influenced by multiple factors including centralized procurement and healthcare cost control policies, as well as changes in the external macroeconomic environment [1] Financial Performance - The company is taking measures to address operational challenges by focusing on sustainable development and maximizing shareholder interests, which includes implementing cost-saving initiatives and enhancing operational efficiency [1] - The company has recognized impairment indicators for certain assets and has made provisions for asset impairment to solidify asset quality [1] - Final financial data will be disclosed in the officially audited 2025 annual report [1]

迈普医学(301033.SZ)公告，公司股东唐莹女士计划通过集中竞价交易及大宗交易方式减持公司股份不 超过84.09万股，占公司总股本的1.2541%。减持期间为自本公告披露之日起15个交易日后的3个月内。 ...